Suptavumab for the Prevention of Medically Attended Respiratory Syncytial Virus Infection in Preterm Infants

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of childhood medically attended respiratory infection (MARI). METHODS: We conducted a randomized, double-blind, placebo-controlled phase 3 trial in 1154 preterm infants of 1 or 2 doses of suptavumab, a human monoclonal antibody that can...

Descripción completa

Detalles Bibliográficos
Autores principales: Simões, Eric A F, Forleo-Neto, Eduardo, Geba, Gregory P, Kamal, Mohamed, Yang, Feng, Cicirello, Helen, Houghton, Matthew R, Rideman, Ronald, Zhao, Qiong, Benvin, Sarah L, Hawes, Alicia, Fuller, Erin D, Wloga, Elzbieta, Pizarro, Jose M Novoa, Munoz, Flor M, Rush, Scott A, McLellan, Jason S, Lipsich, Leah, Stahl, Neil, Yancopoulos, George D, Weinreich, David M, Kyratsous, Christos A, Sivapalasingam, Sumathi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Online Only Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653633/
https://www.ncbi.nlm.nih.gov/pubmed/32897368
http://dx.doi.org/10.1093/cid/ciaa951

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8653633/
https://www.ncbi.nlm.nih.gov/pubmed/32897368
http://dx.doi.org/10.1093/cid/ciaa951

Ejemplares similares